Early Noninvasive Ventilation May Not Be Better for Patients With Acute Respiratory Failure
the ONA take:
Among immunocompromised patients admitted to intensive care units (ICUs) with hypoxemic acute respiratory failure, early noninvasive ventilation did not reduce 28-day mortality compared with oxygen therapy alone, according to a new study published online ahead of print in JAMA.
Although noninvasive ventilation has been recommended to decrease mortality among immunocompromised patients with hypoxemic acute respiratory failure, its effectiveness has remained unclear.
Therefore, researchers sought to evaluate whether early noninvasive ventilation improved survival in these patients.
For the multicenter trial, researchers enrolled 374 critically ill immunocompromised patients at 28 ICUs in France and Belgium.
Of those, nearly 85% were receiving treatment for hematologic malignancies and solid tumors. Participants were randomly assigned to receive early noninvasive ventilation or oxygen therapy alone.
Results showed that at 28 days after randomization, 46 deaths had occurred in the noninvasive ventilation group compared with 50 in the oxygen group (P=0.47). In addition, oxygenation failure occurred in 73 patients and 82 patients, respectively (P=0.20).
Researchers found no significant differences in ICU-acquired infections, duration of mechanical ventilation, or lengths of ICU or hospital stays between the two treatment arms.
The authors note that the study power was limited and this may affect the applicability of the findings.
Early noninvasive ventilation did not reduce 28-day mortality compared with oxygen therapy alone.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|